Live Breaking News & Updates on Menarini Stemline

Stay updated with breaking news from Menarini stemline. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Menarini Silicon Biosystems' s CELLSEARCH® CMMC and HER2-CTC Liquid Biopsy Tests obtain Reimbursement Codes with Preliminary Pricing Determination

- These new Codes are required to access Medicare/Medicaid insurance Reimbursement for novel CELLSEARCH Circulating Multiple Myeloma Cell (CMMC) and HER2 . ....

Laboratory Analyses , Us Centers For Medicare , Menarinisiliconbiosystems Msb Inc , Menarini Silicon Biosystems , Biopsy Tests , Reimbursement Codes , Preliminary Pricing Determination , Multiple Myeloma Cell , Tumor Cell , Current Procedural Terminology , Proprietary Laboratory Analyses ,

A. Menarini Asia-Pacific Holdings Pte. Ltd.: Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem in China to Treat Antimicrobial Resistant Infections

Vaborem, a patented combination of meropenem and vaborbactam, is expected to address the rising prevalence of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in ChinaThe deal brings ....

United States , Chong Zhao , Christine Ann Miller , Maurizio Luongo , Menarini Asia Pacific , Sciclone Pharmaceuticals Holdings Limited , World Health Organization , China Antimicrobial Surveillance Network , Sciclone Pharmaceuticals Holdings , European Union , Menarini Group , Sciclone Pharmaceuticals , Prnewswirea Menarini Asia Pacific Holdings Pte , Melinta Therapeutics , Menarini Asia Pacific Holdings , Chief Executive Officer , License Agreement , Independent States , Clone Pharmaceuticals , Cidara Therapeutics ,

Menarini Industrie Farmaceutiche Riunite: Menarini Group's Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer

Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- ....

United States , France General , Kostenloser Wertpapierhandel , Elcin Barker Ergun , Menarini Group , European Union , Drug Administration , Radius Health Inc , European Society For Medical Oncology , Stemline Therapeutics , Marketing Authorization Application , Chief Executive Officer , Clinical Oncology , European Society , Medical Oncology , Radius Health , Fast Track ,

The Menarini Group and its Subsidiary Stemline Therapeutics: Menarini Group's Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer

Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced ....

United States , France General , Valeria Speroni Cardi , Ashani Lewis , Elcin Barker Ergun , Menarini Group , European Union , Drug Administration , Radius Health Inc , European Society For Medical Oncology , Stemline Therapeutics , Marketing Authorization Application , Chief Executive Officer , Clinical Oncology , European Society , Medical Oncology , Radius Health , New Drug Application , Fast Track , Speroni Cardi ,

Menarini Industrie Farmaceutiche Riunite: Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer

Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from 2L and 3L ER+/HER2- advanced or metastatic breast cancerSubmission ....

New York , United States , Kostenloser Wertpapierhandel , Elcin Barker Ergun , Company New Drug Application , Menarini Group , Drug Administration , European Medicines Agency , Radius Health Inc , Menarini Group Logo , Prescription Drug User Fee Act , Stemline Therapeutics , New Drug Application , Priority Review , Fast Track , Chief Executive Officer , Marketing Authorization Application , Radius Health , New York City ,